Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality
To evaluate image quality of coronary CT angiography (cCTA) after sublingual and transdermal administration of Nitroglycerin. Aim of this prospective research study is to investigate equivalence on image quality after sublingual or transdermal Nitroglycerin administration (H0).
Furthermore, the feasibility of transdermal Nitroglycerin administration will be evaluated.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Scheduled cCTA with contrast.
- Able to comprehend and sign the consent form.
Exclusion Criteria:
- Known hypersensitivity to glyceryl trinitrate, and related organic nitrates.
- Acute circulatory failure associated with marked hypotension (shock).
- Conditions associated with elevated intracranial pressure, cerebral haemorrhage and head trauma.
- Closed-angle glaucoma.
- Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra®), tadalafil (Cialis), or vardenafil (Levitra) within the last 24 hours
- Unstable clinical conditions (i.e. hemodynamic instability, arrhythmias)
- Critical aortic stenosis
- Systolic blood pressure < 90 mmHg
- Pregnant or lactating female; premenopausal women with a positive urine pregnancy test.
- Age under 18
- Unwilling or unable to inform consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Sublingual Nitroglycerin spray
Sublingual Nitroglycerin spray of 0.8 mg
|
Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan.
Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination.
The patch will be placed on the chest or the upper arm.
|
|
Active Comparator: Sublingual Nitroglycerin tablet
Sublingual Nitroglycerin tablet of 0.8 mg
|
Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan.
Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination.
The patch will be placed on the chest or the upper arm.
|
|
Active Comparator: Nitroglycerin skin patch
Nitroglycerin skin patch of 0.8 mg/h
|
Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan.
Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination.
The patch will be placed on the chest or the upper arm.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coronary Artery Diameter Change
Time Frame: obtained on the same day (day 0) of nitroglycerine administration (nitroglycerine is administered during the cCTA exam appointment).
|
Average diameter of coronary arteries at 7 predefined locations in the proximal, mid, and distal segments of the left main, left anterior descending, left circumflex and right coronary artery.
Measurements avoid areas of coronary non-calcified and calcified plaques and measured twice for each location.
Proximal and distal deviation from original measurements is possible in case of plaque.
|
obtained on the same day (day 0) of nitroglycerine administration (nitroglycerine is administered during the cCTA exam appointment).
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016P002417
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.